This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

57/100

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In the context of global ageing, the prevalence of neurodegenerative diseases and dementia, such as Alzheimer's disease (AD), is increasing. However, the current symptomatic and disease-modifying therapies have achieved limited benefits for neurodegenerative diseases in clinical settings. Halting the progress of neurodegeneration and cognitive decline or even improving impaired cognition and function are the clinically meaningful goals of treatments for neurodegenerative diseases. Ageing is the primary risk factor for neurodegenerative diseases and their associated comorbidities, such as vascular pathologies, in elderly individuals. Thus, we aim to elucidate the role of ageing in neurodegenerative diseases from the perspective of a complex system, in which the brain is the core and peripheral organs and tissues form a holistic network to support brain functions. During ageing, the progressive deterioration of the structure and function of the entire body hampers its active and adaptive responses to various stimuli, thereby rendering individuals more vulnerable to neurodegenerative diseases. Consequently, we propose that the prevention and treatment of neurodegenerative diseases should be grounded in holistic antiageing and rejuvenation means complemented by interventions targeting disease-specific pathogenic events. This integrated approach is a promising strategy to effectively prevent, pause or slow down the progression of neurodegenerative diseases.

What this study adds

Evidence grade: Low

This is a narrative review. This review argues that ageing is the primary risk factor for neurodegenerative diseases and proposes that prevention and treatment should be based on holistic antiageing approaches alongside interventions targeting disease-specific events. It offers a perspective rather than testing any specific treatment, so it does not show that any antiageing strategy works in people.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jiang, Q., Liu, J., Huang, S., Wang, X. Y., Chen, X., Liu, G. H., et al. (2025). Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-025-02145-7

Vancouver

Jiang Q, Liu J, Huang S, Wang XY, Chen X, Liu GH, et al. Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances. Signal transduction and targeted therapy. 2025. doi:10.1038/s41392-025-02145-7. PMID: 40059211.

BibTeX

@article{jiang2025-40059211,
  author  = {Jiang, Q. and Liu, J. and Huang, S. and Wang, X. Y. and Chen, X. and Liu, G. H. and Ye, K. and Song, W. and others},
  title   = {{Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances}},
  journal = {Signal transduction and targeted therapy},
  year    = {2025},
  doi     = {10.1038/s41392-025-02145-7},
  pmid    = {40059211},
  url     = {https://doi.org/10.1038/s41392-025-02145-7}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a narrative review. It summarises a field without a fixed search method, so it shows how authors read the evidence rather than measuring it. Use it to find the primary studies, not as a result in itself.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Ageing is the primary risk factor for neurodegenerative diseases and their associated comorbidities, such as vascular pathologies, in elderly individuals.
Thus, we aim to elucidate the role of ageing in neurodegenerative diseases from the perspective of a complex system, in which the brain is the core and peripheral organs and tissues form a holistic network to support brain functions.
During ageing, the progressive deterioration of the structure and function of the entire body hampers its active and adaptive responses to various stimuli, thereby rendering individuals more vulnerable to neurodegenerative diseases.
Consequently, we propose that the prevention and treatment of neurodegenerative diseases should be grounded in holistic antiageing and rejuvenation means complemented by interventions targeting disease-specific pathogenic events.
This integrated approach is a promising strategy to effectively prevent, pause or slow down the progression of neurodegenerative diseases.

Why it matters

This review argues that ageing is the primary risk factor for neurodegenerative diseases and proposes that prevention and treatment should be based on holistic antiageing approaches alongside interventions targeting disease-specific events. It offers a perspective rather than testing any specific treatment, so it does not show that any antiageing strategy works in people.

New to this subject? Start with our plain-English guide: Prevention →

Study details

Evidence strengthLow

How this study scored 57/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Signal transduction and targeted therapy)
Journal's citation record	3 / 4	Signal Transduction and Targeted Therapy: journal h-index 289 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	5 / 7	Cited 156 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	52.0 citations a year over 3 year(s) since 2025
Impact for its field and year	6 / 6	Cited 85.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	3 / 4	Cited 156 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Yan‐Jiang Wang: h-index 67 (OpenAlex, whole career)
Institution's track record	2 / 3	Chinese Academy of Sciences: institution h-index 1,801 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 11 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40059211)
Free to read	2 / 2	Free to read
Total	57 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 44.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Prevention and risk from nearby years

Also in Prevention and risk

265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →